Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin

Lancet

Volumn 353, Issue 9166, 1999, Pages 1763-1764

  Nakad, Antoine ^c   Bataille, Laurent ^c   Hamoir, Vincent ^c   Sempoux, Christine ^c   Horsmans, Yves ^a,b  

^a Clinique Notre Dame   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHENOBARBITAL; SIMVASTATIN;

ACUTE HEPATITIS; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; ENZYME ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER FUNCTION TEST; PRIORITY JOURNAL;

EID: 0033594789     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00569-3     Document Type: Article

References (5)

1. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998; 23: 577-84.
2. Ballare M, Xampanini M, Airoldi G, et al. Hepatotoxicity of hydroxymethyl-glutaryl-coexyme A reductase inhibitors. Minerva Gastroenterol Dietol 1992; 38: 41-44.
3. Koomstra JJ, Ottervanger JP, Fehmers MC, Stricker BH. Clinically manifest liver lesions during use of simvastatin. Ned Tijdschr Geneesk 1996; 140: 846-48.
4. Kocarek TA, Schuetz EG, Strom SC, Fisher RA, Guzelian PS. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab Dispos 1995; 23: 415-21.
5. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A reductase inhibitors. Clin Pharmacokinet 1996; 5: 348-71.